High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections

International Journal of Antimicrobial Agents

Volumn 45, Issue 1, 2015, Pages 90-93

  Routsi, Christina ^a   Kokkoris, Stelios ^a   Douka, Evangelia ^a   Ekonomidou, Foteini ^a   Karaiskos, Ilias ^b   Giamarellou, Helen ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b HYGEIA HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAMASE INHIBITOR; BILIRUBIN; CARBAPENEM; CEPHALOSPORIN; COLISTIN; FIBRINOGEN; QUINOLONE; TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE;

ABDOMINAL INFECTION; ADULT; APACHE; BACTEREMIA; BLOOD CLOTTING; CLINICAL ARTICLE; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; INTENSIVE CARE; LETTER; MALE; MEDIASTINITIS; PARTIAL THROMBOPLASTIN TIME; SEPSIS; SEPTIC SHOCK; THROMBOCYTE COUNT; VENTILATOR ASSOCIATED PNEUMONIA; AGED; ANALOGS AND DERIVATIVES; BACTERIAL INFECTIONS; BLOOD CLOTTING DISORDER; CHEMICALLY INDUCED; CRITICAL ILLNESS; MIDDLE AGED;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BLOOD COAGULATION DISORDERS; CRITICAL ILLNESS; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; PARTIAL THROMBOPLASTIN TIME;

EID: 84920471768     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.07.014     Document Type: Letter

References (6)

1. US Food and Drug Administration. Full prescribing information for Tygacil. FDA; 2010. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/021821s021lbl.pdf [accessed 02.12.13].
2. D. Conde-Estévez, S. Grau, J.P. Horcajada, and S. Lukue Off-label prescription of tigecycline: clinical and microbiological characteristics and outcomes Int J Antimicrob Agents 36 2010 471 472
3. M.E. Falagas, K.Z. Vardakas, K.P. Tsiveriotis, N.A. Triarides, and G.S. Tansarli Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections Int J Antimicrob Agents 44 2014 1 7
4. G. Poulakou, F.V. Kontopidou, E. Paramythiotou, M. Kompoti, M. Katsiari, and E. Mainas Tigecycline in the treatment of infections from multi-drug resistant Gram-negative pathogens J Infect 58 2009 273 284
5. H. Pieringer, B. Schmekal, G. Biesenbach, and E. Pohanka Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline Ann Hematol 89 2010 1063 1064
6. E.J. Ellis-Grosse, T. Babinchak, N. Dartois, G. Rose, E. Loh, and Tigecycline 300 cSSSI Study Group The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam Clin Infect Dis 41 Suppl. 5 2005 S341 S353